Shiyu Capital

Shiyu Capital is a Beijing-based venture capital firm specializing in investments within the healthcare and biotechnology sectors. Founded in September 2014, the firm focuses on equity investments in pharmaceutical and healthcare industries, asset allocation, and wealth management. Its flagship fund, the Danqing Innovative Pharma Industry Fund, targets areas including drug development, biotechnology, healthcare, in vitro diagnostics (IVD), and medical services. The firm's investment philosophy emphasizes deep industry engagement, innovation, professionalism, and concentration, aiming to leverage industrial resources to create value alongside outstanding entrepreneurs.

The firm operates with a team of over 30 investment professionals who possess strong industrial backgrounds and a deep understanding of financial and capital services. Team members have rich experience in both global and domestic capital markets. Shiyu Capital has made 20 investments, with its most recent on February 28, 2024, when Hainan Zhongle raised funding. Notable exits include Biotheus, CARsgen Therapeutics, and Lepu Bio. The firm has raised a single venture fund, Danqing Fund II, announced on April 11, 2019.

In addition to its investment activities, Shiyu Capital is committed to social responsibility. In July 2018, the firm established the Shenzhen Shiyu Children Foundation, a private non-profit organization dedicated to disseminating charitable spirit, providing social assistance, and promoting charity for children, particularly in the field of childhood cancer. The foundation aims to improve public understanding and trust in medical sciences through support, education, and publicity programs, assisting families in obtaining timely and effective help and promoting the development of children's charity in China.